title: [Experimental gene therapy in models of inflammatory arthritis].
abstract: Gene therapy is rheumatoid arthritis is presently in an experimental phase. Genes encoding for antiinflammatory proteins can be transfected in joint cells. Therefore gene encoding for interleukin-1 receptor antagonist has been transfected into synovial cells or into chondrocytes. Gene expression can be maintained as long as 8 weeks after cell transfer. We have reported that clinical and histopathological parameters of collagen-induced arthritis (an animal model of rheumatoid arthritis) can be reduced by engraftment of CHO cells transfected with genes encoding for antiinflammatory cytokines such as interleukine-4 or interleukine-13. Some of the questions which need to be assessed before planning clinical trial are the choice of vectors and the most efficient target cells; and the genes to be transfected have to be chosen among many candidates.
authors.affiliation: Unité de Recherches sur l'Immunorégulation et l'Auto-immunité (INSERM U283), Université René-Descartes, Paris.
authors.forename: N
authors.initials: N
authors.lastname: Bessis
authors.forename: C
authors.initials: C
authors.lastname: Fournier
authors.forename: D
authors.initials: D
authors.lastname: Fradelizi
authors.forename: M C
authors.initials: MC
authors.lastname: Boissier
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D006224:Cricetinae; D004195:Disease Models, Animal; D015316:Genetic Therapy; D011817:Rabbits